Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pittcon Special Report: Bruker Showcases Products, Services in 3 Scientific Markets

By Drug Discovery Trends Editor | March 14, 2016

The new Bruker SiBrickScan (SBS) is the first at-line FTIR instrument allowing for the quantification of interstitial Oxygen in complete Silicon bricks and ingots.  (Credit: Bruker)Bruker Corp., a 2015 R&D 100 winner, is showing no signs of a slowdown in 2016.

The manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis held a press conference at Pittcon 2016 last week in Atlanta to introduce close to a dozen new products in various markets, including pharmaceutical, microscopy, nanoanalysis and more. 

For the pharmaceutical market, the Massachusetts-based company introduced the new Honey Profiling module of the NMR FoodScreener, which has quickly gained acceptance by major global food analysis labs and honey-packers because if its capabilities to rapidly and cost-effectively detect adulteration and mislabeling of content or origin.

Frank Laukien is president & CEO of Bruker Corp. (Credit: Conrad Erb)“It is really quite remarkable how powerful, yet productive and easy-to-use FT-NMR has become in recent years in clinical metabolomics research and small-molecule quantitative mixture analysis, without the need for any chromatography,” Bruker President & CEO Frank Laukien told R&D Magazine in regards to this product. “The reasons for these recent developments and this rapidly emerging trend are really quite fundamental, as in FT-NMR of liquids simply all hydrogen atoms are detected and can be counted, without any quantitative discrimination or suppression effects. As a result, in just a few minutes, fully automated NMR workflows have the fundamental advantage that they can very precisely and robustly quantitate the 100-200 most abundant metabolites or small molecules in body fluids, wine, fruit juices, honey, edible oils, or other beverages, with inherently much tighter quantitative accuracy than even GC-MS or LC-MS.”

Bruker also showcased the SiBrickScan (SBS), the first at-line FTIR instrument allowing for the quantification of interstitial oxygen in complete silicon bricks and ingots. This system is a big step forward for Si wafer producers. Unlike previous approaches, the SBS doesn’t need the preparation of thin samples, but directly determines the oxygen gradient along the ingot main axis for fast and economic QC, according to Bruker.

Additionally, Bruker BioSpin Group introduced LabScape, a flexible new approach to instrument life-cycle management, maintenance and service. The LabScape suite of laboratory services includes maintenance, repair and upgrade agreements for magnetic resonance and preclinical imaging product lines.

Bruker won a 2015 R&D 100 award in the category of Lab Instruments for its BRAVO handheld Raman spectrometer. The company has won close to 20 R&D 100 Awards over the years.

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community! Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE